12 Health Care Stocks Moving In Monday's Intraday Session
Portfolio Pulse from Benzinga Insights
The article highlights significant intraday movements in health care stocks on Monday. Notable gainers include Mustang Bio (MBIO) with a 307.9% increase, Scinai Immunotherapeutics (SCNI) up by 62.17%, and Mirum Pharmaceuticals (MIRM) up by 20.79%. On the losing side, Aerovate Therapeutics (AVTE) saw a massive decline of 93.4%, Ovid Therapeutics (OVID) fell by 69.0%, and Bluejay Diagnostics (BJDX) dropped by 24.71%.
June 17, 2024 | 4:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mustang Bio (MBIO) stock surged by 307.9% to $0.53, significantly increasing its market cap to $14.9 million.
The substantial increase in MBIO's stock price indicates strong positive sentiment or news, likely leading to further short-term gains.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Mirum Pharmaceuticals (MIRM) shares increased by 20.79% to $31.31, with a market cap of $1.4 billion.
The notable increase in MIRM's stock price indicates positive market sentiment, likely leading to short-term gains.
CONFIDENCE 100
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Scinai Immunotherapeutics (SCNI) stock rose by 62.17% to $5.66, raising its market cap to $3.2 million.
The significant rise in SCNI's stock price suggests positive developments or investor sentiment, likely leading to short-term gains.
CONFIDENCE 100
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Aerovate Therapeutics (AVTE) shares plummeted by 93.4% to $1.62, reducing its market cap to $46.7 million.
The drastic decline in AVTE's stock price suggests severe negative news or sentiment, likely leading to further short-term losses.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
NEGATIVE IMPACT
Bluejay Diagnostics (BJDX) shares declined by 24.71% to $0.38, with a market cap of $1.1 million.
The notable decline in BJDX's stock price suggests negative sentiment, likely leading to further short-term losses.
CONFIDENCE 100
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Ovid Therapeutics (OVID) stock fell by 69.0% to $1.02, decreasing its market cap to $72.3 million.
The significant drop in OVID's stock price indicates negative developments or sentiment, likely leading to further short-term losses.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100